Syndrome of inappropriate antidiuretic hormone medical therapy: Difference between revisions

Jump to navigation Jump to search
Line 7: Line 7:


==Medical treatment of SIADH==
==Medical treatment of SIADH==
The mainstay of therapy for [[SIADH]]  
The mainstay of [[therapy]] for [[SIADH]]  


'''Mild''':
'''Mild''':


*[[Fluid]] restriction (<800ml/day)<ref name="pmid10824078">{{cite journal |vauthors=Adrogué HJ, Madias NE |title=Hyponatremia |journal=N. Engl. J. Med. |volume=342 |issue=21 |pages=1581–9 |year=2000 |pmid=10824078 |doi=10.1056/NEJM200005253422107 |url=}}</ref>
*[[Fluid]] restriction (<800ml/day)


'''Moderat'''e:
'''Moderat'''e:


*[[Oral salt tablets]] with [[loop diuretics]]( 20 mg of Furosemide orally twice a day)<ref name="pmid6805839">{{cite journal |vauthors=Decaux G, Waterlot Y, Genette F, Hallemans R, Demanet JC |title=Inappropriate secretion of antidiuretic hormone treated with frusemide |journal=Br Med J (Clin Res Ed) |volume=285 |issue=6335 |pages=89–90 |year=1982 |pmid=6805839 |pmc=1498910 |doi= |url=}}</ref>
*Oral salt tablets with [[loop diuretics]]( 20 mg of [[Furosemide]] orally twice a day)


'''Severe''':
'''Severe''':
* 3% hypertonic saline( if [[sodium]] level falls below 125meq/l )
* 3% [[hypertonic]] saline( if [[sodium]] level falls below 125meq/l )
* 100 ml of 3% saline, raises sodium by 1.5meq/l in men and 2 meq/l in women
* 100 ml of 3% saline, raises sodium by 1.5meq/l in men and 2 meq/l in [[Women's College Hospital|women]]
* Goal of rate of increase is an elevation in serum sodium of 4-6 meq/day in the first 2-4 hrs
* Goal of rate of increase is an elevation in serum [[sodium]] of 4-6 meq/day in the first 2-4 hrs
* The limit is 8meq/day
* The limit is 8meq/day
   
   
Line 26: Line 26:


*[[Vasopressin]]-2 receptor [[antagonists]] such as [[conivaptan]] or [[tolvaptan]]  
*[[Vasopressin]]-2 receptor [[antagonists]] such as [[conivaptan]] or [[tolvaptan]]  
* Conivaptan (20mg loading dose followed by continuous infusion of 40mg/day for four days)<ref name="pmid17664863">{{cite journal |vauthors=Zeltser D, Rosansky S, van Rensburg H, Verbalis JG, Smith N |title=Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia |journal=Am. J. Nephrol. |volume=27 |issue=5 |pages=447–57 |year=2007 |pmid=17664863 |doi=10.1159/000106456 |url=}}</ref>
* [[Conivaptan]] (20mg loading dose followed by continuous infusion of 40mg/day for four days)
* Tolvaptan should not be used longer than thirty days and patients with liver disease<ref name="pmid17105757">{{cite journal |vauthors=Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C |title=Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia |journal=N. Engl. J. Med. |volume=355 |issue=20 |pages=2099–112 |year=2006 |pmid=17105757 |doi=10.1056/NEJMoa065181 |url=}}</ref>
* Tolvaptan should not be used longer than thirty days and patients with [[liver]] [[disease]]
'''Miscellaneous'''
'''Miscellaneous'''


*[[Demeclocycline]]: Demeclocycline(300-600mg twice a day)It is a tetracycline derivative which induces [[drug-induced]] [[diabetes insipidus]] by acting on the [[collecting tubule]] cell to diminish its responsiveness to [[ADH]].The role is limited in [[emergency]] care due to the slow onset of action<ref name="pmid413037">{{cite journal |vauthors=Forrest JN, Cox M, Hong C, Morrison G, Bia M, Singer I |title=Superiority of demeclocycline over lithium in the treatment of chronic syndrome of inappropriate secretion of antidiuretic hormone |journal=N. Engl. J. Med. |volume=298 |issue=4 |pages=173–7 |year=1978 |pmid=413037 |doi=10.1056/NEJM197801262980401 |url=}}</ref>
*[[Demeclocycline]]: Demeclocycline(300-600mg twice a day) is a [[tetracycline]] derivative which induces [[drug-induced]] [[diabetes insipidus]] by acting on the [[collecting tubule]] cell to diminish its responsiveness to [[ADH]].The role is limited in [[emergency]] care due to the slow onset of [[Action Ambulance|action]]


*Urea: [[Urea]], at a dose of15-30 g/day, increases [[Urinary system|urinary]] [[solute]] excretion and enhances [[water]] [[excretion]]<ref name="pmid22403276">{{cite journal |vauthors=Soupart A, Coffernils M, Couturier B, Gankam-Kengne F, Decaux G |title=Efficacy and tolerance of urea compared with vaptans for long-term treatment of patients with SIADH |journal=Clin J Am Soc Nephrol |volume=7 |issue=5 |pages=742–7 |year=2012 |pmid=22403276 |doi=10.2215/CJN.06990711 |url=}}</ref>
*Urea: [[Urea]], at a dose of15-30 g/day, increases [[Urinary system|urinary]] [[solute]] excretion and enhances [[water]] [[excretion]]


*Special consideration: [[Hyponatremia]] is the most common [[electrolyte]] abnormality in [[SIADH]]. So, the rate at which [[sodium]] is corrected is very important in clinical settings. It depends on the degree of [[hyponatremia]], duration (acute or chronic), and symptomatology
*Special consideration: [[Hyponatremia]] is the most common [[electrolyte]] abnormality in [[SIADH]]. So, the rate at which [[sodium]] is corrected is very important in [[clinical]] settings. It depends on the degree of [[hyponatremia]], duration (acute or chronic), and symptomatology


{| style="border: 0px; font-size: 90%; margin: 3px; width: 1000px" align="center"
{| style="border: 0px; font-size: 90%; margin: 3px; width: 1000px" align="center"

Revision as of 19:43, 31 August 2017

Syndrome of inappropriate antidiuretic hormone Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differential Diagnosis

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Syndrome of inappropriate antidiuretic hormone medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Syndrome of inappropriate antidiuretic hormone medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Syndrome of inappropriate antidiuretic hormone medical therapy

CDC on Syndrome of inappropriate antidiuretic hormone medical therapy

Syndrome of inappropriate antidiuretic hormone medical therapy in the news

Blogs on Syndrome of inappropriate antidiuretic hormone medical therapy

Directions to Hospitals Treating Syndrome of inappropriate antidiuretic hormone

Risk calculators and risk factors for Syndrome of inappropriate antidiuretic hormone medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vindhya BellamKonda, M.B.B.S [2]

Overview

Treatment of syndrome of inappropriate antidiuretic hormone depends on the etiology. For immediate improvement, all patients with SIADH require strict restriction of their dailywater intake and correction of serum sodium levels. The serum sodium can can be corrected depending on the initial sodium levels of the patient. Mild cases can be managed easily with exclusive fluid restriction. Moderate cases of SIADH are treated with loop diuretics and normal saline, whereas, 3% hypertonic saline may be used in severe cases. In emergency settings, Vasopressin-2 receptor antagonists ( conivaptan ortolvaptan) are used. The definitive treatment of SIADH involves treatment of the underlying condition. Urea, demeclocycline and lithium are also used in the treatment of SIADH

Medical treatment of SIADH

The mainstay of therapy for SIADH

Mild:

  • Fluid restriction (<800ml/day)

Moderate:

Severe:

  • 3% hypertonic saline( if sodium level falls below 125meq/l )
  • 100 ml of 3% saline, raises sodium by 1.5meq/l in men and 2 meq/l in women
  • Goal of rate of increase is an elevation in serum sodium of 4-6 meq/day in the first 2-4 hrs
  • The limit is 8meq/day

Emergency setting:

Miscellaneous

Acute hyponatremia Chronic hyponatremia
  • Vasopressin-2 receptor antagonists(conivaptan and tolvaptan)
  • In rare medical emergencies, more commonly seen in cardiology in the context of hypervolemic severe hyponatremia rather than in SIADH
    • Continuous veno-venous hemofiltration (CVVH)
    • Slow, low-efficiency daily dialysis (SLEDD) have been used to improve hyponatremia

References